Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Femasys Inc (FEMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/03/2025: FEMY (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -8.94% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 29.41M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 421079 | Beta -2.85 | 52 Weeks Range 0.86 - 1.84 | Updated Date 04/1/2025 |
52 Weeks Range 0.86 - 1.84 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -812.03% |
Management Effectiveness
Return on Assets (TTM) -55.3% | Return on Equity (TTM) -182.18% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28379921 | Price to Sales(TTM) 18.05 |
Enterprise Value 28379921 | Price to Sales(TTM) 18.05 | ||
Enterprise Value to Revenue 22.51 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 22898500 | Shares Floating 19971185 |
Shares Outstanding 22898500 | Shares Floating 19971185 | ||
Percent Insiders 12.22 | Percent Institutions 13.88 |
Analyst Ratings
Rating 4.5 | Target Price 8.25 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Femasys Inc
Company Overview
History and Background
Femasys Inc. is a biomedical company focused on developing solutions for the unmet needs in women's healthcare, particularly permanent contraception. Founded in 2004, the company has focused on developing and commercializing innovative medical devices.
Core Business Areas
- Permanent Contraception: Focuses on the development and commercialization of the FemaSeed permanent contraception system. Currently not commercially available.
Leadership and Structure
The leadership team is composed of experienced professionals in the medical device industry, and the company has a typical corporate structure with a board of directors and various management positions.
Top Products and Market Share
Key Offerings
- FemaSeed: FemaSeed is a potential non-surgical permanent contraception method, designed to use a woman's body to naturally close her fallopian tubes. It is not yet available to consumers and is in clinical trials. Competitors include Essure (now discontinued but formerly Bayer's product), and surgical sterilization procedures like tubal ligation. Market share data is unavailable as it is not commercialized.
Market Dynamics
Industry Overview
The women's health market, particularly contraception, is a significant and growing market. Demand is influenced by factors such as women's reproductive choices, healthcare access, and advancements in medical technology.
Positioning
Femasys is attempting to position itself in the permanent contraception market with a non-surgical approach to sterilization.
Total Addressable Market (TAM)
The global permanent contraception market is estimated to be in the billions of dollars. Femasys's position within the TAM will be determined by the success of FemaSeed and its adoption rate if approved and commercialized.
Upturn SWOT Analysis
Strengths
- Innovative technology (non-surgical approach to permanent contraception)
- Focus on women's health
- Potential to address unmet needs in contraception
Weaknesses
- Dependence on successful clinical trials and regulatory approvals
- Limited commercialization history
- Reliance on external funding
Opportunities
- Growing demand for non-surgical contraception options
- Expansion into new markets
- Potential partnerships with healthcare providers
Threats
- Competition from established contraception methods
- Regulatory hurdles and delays
- Potential for adverse events or safety concerns
Competitors and Market Share
Key Competitors
- BDX
- JNJ
- MRK
Competitive Landscape
Femasys faces significant competition from established medical device companies, especially if Femasys is unable to get the product approved.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be evaluated based on revenue growth and market share gains.
Future Projections: Future growth projections would be based on analyst estimates for revenue, earnings, and market share.
Recent Initiatives: Recent strategic initiatives would include product development updates, regulatory submissions, and partnerships.
Summary
Femasys is a biomedical company that is attempting to innovate the women's health market. A large part of the company's future success hinges on clinical trials and regulatory approval of FemaSeed. Strong competition in the women's health space could prove difficult. A successful market adoption of FemaSeed could lead to considerable growth.
Similar Companies
BDX
Becton Dickinson and Company
BDX
Becton Dickinson and Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Femasys Inc
Exchange NASDAQ | Headquaters Suwanee, GA, United States | ||
IPO Launch date 2021-06-18 | Founder, President, CEO & Director Ms. Kathy Lee-Sepsick M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees - | Website https://www.femasys.com |
Full time employees - | Website https://www.femasys.com | ||
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.